Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Can Oxytocin Level Predict Postpartum Depression?

NCT02020148
Conditions
Postpartum Depression
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Bipolar Disorder
Interventions
i-IPSRT, Written Psychoeducation
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Other Gastrointestinal Disorders, Cramp, Abdominal
Interventions
Funny/Amusing Video Clips, Horror/Scary Video Clips, Thrilling/Suspenseful Video Clips
Other
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

Games to Overcome Late Life Depression

NCT02229188
Conditions
Major Depressive Disorder
Interventions
Problem Solving Therapy, Evolution, Words
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder

NCT00626340
Conditions
Menopause, Depression
Interventions
MDD diagnosis and Estrogen treatment, MDD diagnosis and Fluoxetine treatment, MDD diagnosis with both Estrogen and Fluoxetine treatment, No depression and estrogen treatment
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Major Depression, Bipolar Disorder
Interventions
Prevalence
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more
Conditions
Depressive Disorder, Major
Interventions
GSK561679, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Cerritos, California • San Diego, California • Torrance, California + 15 more
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Tocilizumab, Placebo, Whole-Body Hyperthermia
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity, Depression
Interventions
I-CARE2
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Bipolar Type II Disorder
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
Stanley Medical Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 4 Interventional Results available

Tianeptine for Treatment Resistant Depression

NCT04249596
Conditions
Treatment Resistant Depression
Interventions
Tianeptine Sodium
Drug
Lead sponsor
Jonathan A. Javitch, MD, PhD
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Stanford, California • New York, New York
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Dan Iosifescu
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orangeburg, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

NCT01250873
Conditions
Major Depressive Disorder
Interventions
LY2216684, Sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Nicotine Dependence, Bipolar Disorder
Interventions
Counseling/Healthy Lifestyle, Counseling/Managing Mood
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Social Determinants in Cardiovascular Health and Vascular Function

NCT05772221
Conditions
Social Determinants of Health, Major Depressive Disorder, Cardiovascular Diseases
Interventions
Screening
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

NCT07092605
Conditions
Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
Interventions
GLP-1, Placebo
Drug
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Major Depressive Disorder
Interventions
Dose-matched placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
Completed Not applicable Interventional Results available

Motivational Interviews for Depression in Primary Care

NCT01114334
Conditions
Major Depression
Interventions
Guideline-Based Medical Management, Motivational Interviewing for Depression
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Bipolar Disorder, Cocaine Dependence
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Dallas, Texas